Life Sciences · Biotech · Exit
Selective kinase inhibitors, acquired by Gedeon Richter
Investment profile
The company
BCI Pharma developed highly potent, selective kinase inhibitors from its proprietary chemical libraries. Its lead focus was neuropathic pain, with further programmes in cancer and neuroinflammation. Its model was to partner with larger pharmaceutical companies at an early stage to co-develop its molecules. In 2024, the company was acquired by Hungarian pharmaceutical group Gedeon Richter.
Related news
01 · Exit · 25 June 2024
L'Echo annonce l'acquisition de BCI Pharma par le groupe pharmaceutique hongrois Gedeon Richter.
Read the article02 · Exit · June 2024
Gedeon Richter acquired BCI Pharma, a biotech focused on kinase inhibitors for neuropathic pain. The transaction marks a Fund I exit.
Read the article
